Navigation Links
Michael R. Bristow, M.D. Ph.D. Joins Nile Therapeutics Scientific Advisory Board
Date:10/7/2010

SAN MATEO, Calif., Oct. 7 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX), a biopharmaceutical company focused on the development of novel therapeutics for cardiovascular disease, today announced that Michael R. Bristow, M.D. Ph.D. has joined the Scientific Advisory Board overseeing the development of CD-NP, a dual natriuretic peptide receptor agonist in development for the treatment of acute decompensated heart failure.

Dr. Bristow, a recognized leader in the heart failure community, is a Professor of Medicine and the former Head of Cardiology at the University of Colorado Health Sciences Center, where he has been since October 1991. Dr. Bristow was a founder of ARCA biopharma, a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases. Dr. Bristow currently serves as Director, President and Chief Executive Officer of ARCA biopharma. Dr. Bristow was the principal founder of Myogen, biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for the treatment of cardiovascular and pulmonary disease. Dr. Bristow served as Myogen's Chief Science and Medical Officer from October 1996 to February 2006 and as a Scientific Advisor to Myogen from February 2006 until the acquisition of Myogen by Gilead Sciences, Inc. in November 2006. Dr. Bristow is also a founder of Miragen Therapeutics, a Boulder, CO based microRNA company.

"We are extremely pleased to welcome Dr. Bristow to our advisory board," said Joshua A. Kazam, Nile's CEO. "We believe that his depth of knowledge in the field of heart failure and his breadth of experience in drug development and commercialization will help us achieve the full potential of CD-NP and our natriuretic peptide program."

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceut
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director
2. ERT Announces Upcoming Retirement of Michael McKelvey as Chief Executive Officer
3. Sleeve Gastrectomy Procedure With Dr. Michael Feiz Serves as a Highly Effective Alternative to Lap Band Surgery
4. FDA CONSUMER HEALTH INFORMATION - Combating Misuse and Abuse of Prescription Drugs: Q&A with Michael Klein, Ph.D.
5. Sangamo BioSciences Receives Michael J. Fox Foundation Funding to Develop Novel Drug for the Treatment of Parkinsons Disease
6. Michael W. Marine Appointed CEO of Sabin Vaccine Institute
7. Michael J. Fox Foundation Awards $2.1 Million to Drive Six Industry Teams Pre-Clinical Development of Neuroprotective Parkinsons Therapies
8. D-M-S Holdings, Inc. Announces the Filing of a Lawsuit Against Veridian Healthcare, LLC, Steven M. Bisulca and Michael Mazza
9. Kendle Appoints J. Michael Sprafka, MPH, PhD, Vice President, Kendle Consulting
10. Takeda San Francisco, Inc. Appoints Michael Buckley, Ph.D. Vice President of Process Sciences
11. Sigma-Aldrich(R) Receives Award From Michael J. Fox Foundation to Develop Parkinsons Disease Research Models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... QC , Nov. 20, 2014 /CNW Telbec/ - ... to announce the following appointments: ... team in the newly created role of Chief Commercial ... BioPhotonic system using topical photoconverter gel for the treatment ... surgical and traumatic wounds, recently approved in ...
(Date:11/21/2014)... 20, 2014 Depomed, Inc. (NASDAQ: DEPO ) ... 26 th Annual Healthcare Conference in New York ... conference is scheduled for 8:00 am EST (5:00 am PST) on ... webcast can be accessed via the Investor Relations page of the ... will be archived for 30 days on the company,s website. ...
(Date:11/21/2014)... 2014   Wellcentive , the industry leader ... organizations, announced today being named one of the ... Award .  Sponsored by Intel, the world leader ... year, recognizes companies developing leading-edge technology and unique ... Wellcentive,s Mason Beard , ...
Breaking Medicine Technology:KLOX Technologies announces executive appointments 2KLOX Technologies announces executive appointments 3KLOX Technologies announces executive appointments 4Depomed To Present At Piper Jaffray 26th Annual Healthcare Conference 2Wellcentive Named Finalist for 2014 Intel Innovation Award 2Wellcentive Named Finalist for 2014 Intel Innovation Award 3
... Launches 1,000-Patient Lung Cancer Diversity Study, CHICAGO, June ... the leading cause of cancer death in,African-Americans, with ... deaths expected this year.(i) Equally devastating, lung,cancer is ... men and the,second leading cause of cancer death ...
... an overall CBR of 52% which compares ... CITY, QC, June 04, 2007 /PRNewswire-FirstCall/ - ... focused on,endocrine therapy and oncology, today announced ... outlining Phase 1 and,Phase 2 results for ...
Cached Medicine Technology:Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 2Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 3Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 4Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 5Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 6Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 7Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 8Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 9Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 10Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 11AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting 2AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting 3AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting 4
(Date:11/21/2014)... Florida (PRWEB) November 21, 2014 Nature’s Sleep is ... Sleep contest . The contest calls for the creation of any ... a photo — that encompasses sleep, a bed or a mattress. ... year,” said Alan Hirschhorn, Vice President of Marketing for Nature’s Sleep, ... an array of more than 10,000 creative entries from some very ...
(Date:11/21/2014)... HealthDay Reporter THURSDAY, Nov. 20, 2014 ... of a still-beating heart has the potential to improve the ... new study. Heart patients who received the gel implant ... hundreds of feet farther during a six-minute walk test, said ... cardiovascular division at Washington University School of Medicine and a ...
(Date:11/21/2014)... HealthDay Reporter THURSDAY, Nov. ... excess or binge drink are not alcoholics, a new U.S. ... who drink too much aren,t dependent on alcohol. But one ... Centers for Disease Control and Prevention. , , "A lot of ... alcoholics," said study co-author Dr. Robert Brewer, the leader of ...
(Date:11/18/2014)... November 18, 2014 Cristcot Inc., ... development and commercialization of specialized drug delivery systems, ... granted Cristcot a patent for the technology, which ... Sephure®. , The patent was awarded to ... rights have been assigned to Cristcot Inc. The ...
(Date:11/18/2014)... HealthDay Reporter MONDAY, ... cholesterol down to extremely low levels with a combination ... in high-risk patients with clogged arteries, a new study ... when taking Vytorin, a drug that combines a cholesterol-lowering ... said principal investigator Dr. Christopher Cannon, a cardiologist at ...
Breaking Medicine News(10 mins):Health News:Nature’s Sleep Kicks Off their 2nd Art Of Sleep Contest 2Health News:Gel Implant Might Help Fight Heart Failure 2Health News:Gel Implant Might Help Fight Heart Failure 3Health News:Many People Who Drink a Lot Aren't Alcoholics: CDC 2Health News:Many People Who Drink a Lot Aren't Alcoholics: CDC 3Health News:Japanese Patent Office Grants Patent to Cristcot Inc. 2Health News:Cholesterol Drug Vytorin Linked to Reduced Heart Attack Risk 2Health News:Cholesterol Drug Vytorin Linked to Reduced Heart Attack Risk 3
... HARRISBURG, Pa. , Sept. 8 ... for subsidized health insurance coverage, state Insurance Commissioner Joel Ario today urged ... that will give Pennsylvania and other states tools needed to fix the ... , "Lost in the din of the recent town hall ...
... Delta Health , an InfoLogix, ... that it has been selected by Hennepin County Medical Center in ... impact margins through productivity management. , , (Logo: ... , Delta Health has helped hospitals across North America ...
... , NEW YORK, Sept. 8 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) ... that it has filed a patent for a novel ... thus has blockbuster potential as a new anti-cancer drug. ... which is highly reactive to prostate cancer cells, and ...
... Sept. 8 MRSA Survivors Network, the Chicago-based nonprofit and official ... lift the veil of secrecy surrounding MRSA. The history making ... October 1st. The 2009 theme is "You Can Not Change What ... http://www.newscom.com/cgi-bin/prnh/20090825/DC65136LOGO ) , , Founder ...
... , NEW YORK, Sept. 8 NeoStem, ... pioneering the pre-disease collection, processing and long-term storage of adult stem ... Robin Smith, M.D., MBA, will present on the Company,s latest strategic ... New York Palace Hotel in New York City on September 9-11, ...
... , , WALTHAM, Mass., ... the global authority on medical technology market intelligence, the ... experience considerable growth in sales over the next five ... 2009 report finds, however, that product safety issues ...
Cached Medicine News:Health News:Insurance Commissioner Says Federal Health Care Reform Necessary to Fix a Broken System 2Health News:Delta Health, an InfoLogix Company, Wins Engagement with Hennepin County Medical Center for Strategic Cost Management 2Health News:Delta Health, an InfoLogix Company, Wins Engagement with Hennepin County Medical Center for Strategic Cost Management 3Health News:Genova files patent for new prostate cancer treatment 2Health News:MRSA Activists to Lift the Veil of Secrecy on World MRSA Day 2Health News:NeoStem to Present at Rodman & Renshaw's 11th Annual Healthcare Conference 2Health News:NeoStem to Present at Rodman & Renshaw's 11th Annual Healthcare Conference 3Health News:Will the FDA Ban Hydroquinone in Pigment Control Products? 2Health News:Will the FDA Ban Hydroquinone in Pigment Control Products? 3
... MedPoint™, a Medication Administration Control System, ... assurance that they are administering the ... used with a bar coded patient ... extends the benefits of the hospital's ...
... MediMAR™ is the newest Mediware ... medication administration record. MediMAR produces a ... patient's medication profile, including clinician orders, ... to medication administration or alerts that ...
... When it comes to medication administration, ... afford to make. The solution is the ... a highly-scalable bar-coded medication administration system, suitable ... also be used stand-alone, networked, or as ...
... Outlook® Safety Infusion System is designed to ... drug, and the right dose. Available in ... Outlook® Safety Infusion System allows hospitals to ... meet their needs. DoseGuard™ dose limit technology ...
Medicine Products: